Top Markets
Coin of the day
Satsuma Pharmaceuticals, Inc. Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc.

STSA
Rangering i aksjer #29910
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies for the rapid relief of migraines. Its lead therapeutic candidate, STS101, is an integrated drug-device system comprising a proprietary dry-powder formulation of dihydroergotamine mesylate. Currently, STS101 is progressing through its pivotal SUMMIT Phase 3 efficacy trials and is designed for self-administration via a specialized, pre-filled, single-use nasal delivery device. Established in 2016, the company maintains its headquarters in South San Francisco, California.
Aksjekurs
$1.10
Sist synkronisert: 2023-06-07
Markedsverdi
$19.12M
Endring (1 dag)
-0.90%
Endring (1 år)
0.00%
Land
US
Handel Satsuma Pharmaceuticals, Inc. (STSA)

Kategori

EPS for Satsuma Pharmaceuticals, Inc. (STSA)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Satsuma Pharmaceuticals, Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Satsuma Pharmaceuticals, Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter